Yara Ruiz García

Dr. Yara Ruiz García

orcid

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 October 2021 in npj Vaccines
Verified
Journal Article
Open access
PDF file
YGYara Ruiz García
Yara Ruiz García
WSWoo-Yun Sohn
Woo-Yun Sohn
KSKate Seib
Kate Seib
MTMuhamed-Kheir Taha
Muhamed-Kheir Taha
JVJulio A. Vázquez
Julio A. Vázquez
RBRafik Bekkat-Berkani
Rafik Bekkat-Berkani
Infections with Neisseria meningitidis and Neisseria gonorrhoeae have different clinical manifestations, but the bacteria share up to 80–90% genome sequence identity. The recombinant meningococcal serogroup B (MenB) vaccine 4CMenB consists of four antigenic components that can be present in non-B meningococcal and gonococcal strains. This comprehensive review summarizes scientific evidence on the genotypic and phenotypic similarities between vaccine antigens and their homologs expressed by non-B meningococcal and gonococcal strains. It also includes immune responses of 4CMenB-vaccinated individuals and effectiveness and impact of 4CMenB against these strains. Varying degrees of strain coverage were estimated depending on the non-B meningococcal serogroup and antigenic repertoire. 4CMenB elicits immune responses against non-B meningococcal serogroups and N. gonorrhoeae. Real-world evidence showed risk reductions of 69% for meningococcal serogroup W clonal complex 11 disease and 40% for gonorrhea after 4CMenB immunization. In conclusion, functional antibody activity and real-world evidence indicate that 4CMenB has the potential to provide some protection beyond MenB disease.

9 June 2025 in Human Vaccines & Immunotherapeutics
Verified
Journal Article
Open access
DHDiane M. Harper
Diane M. Harper
JNJosé A. Navarro-Alonso
José A. Navarro-Alonso
FBF. Xavier Bosch
F. Xavier Bosch
JPJorma Paavonen
Jorma Paavonen
MSMargaret Stanley
Margaret Stanley
YGYara Ruiz García
Yara Ruiz García
Cervical cancer is a preventable disease for which vaccines are available to provide long-term protection against human papillomavirus (HPV) infection. This systematic literature review (SLR) was performed to summarize the efficacy, effectiveness, impact, duration of protection, and safety profile of four licensed HPV vaccines against infection, precursor lesions, and cervical cancer. Data was extracted from published reports. The search resulted in 1,136 studies, of which 54 were selected for this review. A substantial decrease in the prevalence of oncogenic HPV types, high-grade cervical lesions, and cervical cancer was found in countries with high vaccine coverage and routine vaccination programs. Post-licensure studies of HPV vaccines have reported high efficacy, effectiveness, and health impact across settings and age groups. Studies emphasize vaccination in younger age groups. These findings may inform future discussions about HPV vaccination strategies.

2 January 2023 in Human Vaccines & Immunotherapeutics
Verified
Journal Article
Open access
LTLitjen (L.J) Tan
Litjen (L.J) Tan
MSMarco Aurelio Palazzi Safadi
Marco Aurelio Palazzi Safadi
MHMichael Horn
Michael Horn
CBCristina Regojo Balboa
Cristina Regojo Balboa
EMElena Moya
Elena Moya
YGYara Ruiz García
Yara Ruiz García
Invasive meningococcal disease is a life-threatening infection preventable through vaccination. Pediatric vaccination rates have declined during the coronavirus disease 2019 (COVID-19) pandemic. This survey aimed to understand how parents’ attitudes and behaviors have changed during the pandemic with regard to immunization and, more specifically, meningococcal vaccination. An online survey was emailed to parents of eligible children 0–4 years, following the selection process from UK, France, Germany, Italy, Brazil, Argentina, and Australia; and of adolescents 11–18 years from US. Data collection took place 19 January–16 February 2021. Quotas were set to ensure a representative sample. Eleven questions relating to general perceptions around vaccination and attitudes and behaviors toward meningitis vaccination were displayed. On 4,962 parents (average 35 years) participating in the survey, most (83%) believed important for their child to continue receiving recommended vaccines during the COVID-19 pandemic. Nearly half of routine vaccine appointments were delayed or canceled due to the pandemic, and 61% of respondents were likely to have their children catch up once COVID-19 restrictions were lifted. 30% of meningitidis vaccination appointments were canceled or delayed during the pandemic, and 21% of parents did not intend to reschedule them because of lockdown/stay at home regulations, and fear of catching COVID-19 in public places. It is crucial to communicate clear instructions to health workers and the general population and to provide appropriate safety precautions in vaccination centers. This will help to maintain vaccination rates and limit infections to prevent future outbreaks. What is the context? What is new? What is the impact?

2 January 2023 in Human Vaccines & Immunotherapeutics
Verified
Journal Article
Open access
MGMarina George
Marina George
Jaime Jesús Pérez-MartínJaime Jesús Pérez-Martín
Jaime Jesús Pérez-Martín
MAMohammad AbdelGhany
Mohammad AbdelGhany
FGFoteini Gkalapi
Foteini Gkalapi
NJNicolas Jamet
Nicolas Jamet
VBValérie Berlaimont
Valérie Berlaimont
The hexavalent vaccines DT3aP-HBV-IPV/Hib and DT2aP-HBV-IPV-Hib are routinely used for primary immunization of infants against diphtheria, tetanus, pertussis, hepatitis B virus, poliomyelitis, and Haemophilus influenzae type b. A recent publication showed that after primary immunization with these vaccines, the odds ratios of adverse reactions (ARs) were significantly lower for DT3aP-HBV-IPV/Hib than for DT2aP-HBV-IPV-Hib. Our aim is to understand the impact of the various reactogenicity profiles at country level by comparing the ARs induced by one dose of DT3aP-HBV-IPV/Hib versus DT2aP-HBV-IPV-Hib in the primary infant immunization course. A mathematical projection tool was developed to simulate vaccination of infants with both vaccines in six countries: Austria, the Czech Republic, France, Jordan, Spain, and the Netherlands. Proportions of three local and five systemic ARs of interest for both vaccines were based on findings from a previous meta-analysis of ARs in infants. The absolute risk reductions calculated ranged from 3.0% (95% confidence interval [CI]: 2.8%–3.2%) for “Swelling at the injection site, any grade” to 10.0% (95% CI: 9.5%–10.5%) for “Fever, any grade.” The difference in occurrence of the AR “Fever, any grade” between vaccines in 2020 ranged from over 7,000 in Austria to over 62,000 in France. Over 5 years, this would amount to a reduction of over 150,000 ARs in Austria and over 1.4 million ARs in France when using DT3aP-HBV-IPV/Hib instead of DT2aP-HBV-IPV-Hib. In conclusion, the estimated numbers of ARs following hexavalent vaccination in six countries showed that vaccination of infants with DT3aP-HBV-IPV/Hib could lead to fewer ARs than vaccination with DT2aP-HBV-IPV-Hib. Vaccination of infants against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis, and Haemophilus influenzae type b is often performed with combined vaccines against these six diseases. In many countries, these are the first vaccinations received by infants, and potential adverse reactions could affect compliance with future vaccinations. A previous study examined two of the combined vaccines, DT3aP-HBV-IPV/Hib and DT2aP-HBV-IPV-Hib, and showed that local adverse reactions at the injection site (pain, redness, and swelling) and general adverse reactions (fever, drowsiness, irritability, persistent crying, and lack of appetite) were less common after vaccination with DT3aP-HBV-IPV/Hib than with DT2aP-HBV-IPV-Hib. To understand the impact of this finding at a population level, we compared the adverse reactions caused by the hypothetical administration of the two vaccines under similar conditions. We simulated the vaccination of infants with both vaccines in six countries: Austria, the Czech Republic, France, Jordan, Spain, and the Netherlands. The simulation showed that the DT3aP-HBV-IPV/Hib vaccine could reduce cases of swelling at the injection site by 3% and fever by 10%. For the year 2020, the resulting reduction in the estimated number of fever occurrences would have ranged from over 7,000 in Austria to over 62,000 in France. In total, adverse reactions avoided could hypothetically have ranged from 30,781 in Austria to 269,025 in France. Over 5 years, this could have avoided an estimated number of adverse reactions of over 150,000 in Austria to over 1.4 million in France. In conclusion, such a switch of vaccine could substantially reduce adverse reactions.

10 October 2026 in Clinical and Translational Allergy
Verified
Journal Article
Open access
JGJosé Carlos García‐Robaina
José Carlos García‐Robaina
CGCristina González‐Colino
Cristina González‐Colino
GHGuacimara Lucia Hernández‐Santana
Guacimara Lucia Hernández‐Santana
ERElena Rodríguez‐Plata
Elena Rodríguez‐Plata
MGMónica González‐Afonso
Mónica González‐Afonso
JDJudith Díaz-García
Judith Díaz-García
Background: House dust mite (HDM)‐induced respiratory allergy is a major global health problem. Species distribution varies by region and climate; Blomia tropicalis is prevalent in tropical and subtropical areas and often coexists with Dermatophagoides spp. Although allergen immunotherapy (AIT) reduces symptoms and medication use, real‐world evidence for formulations including B. tropicalis remains limited. Objectives: To evaluate the real‐world effectiveness and safety of triple‐mite subcutaneous immunotherapy (SCIT) with glutaraldehyde‐polymerized extracts of Dermatophagoides pteronyssinus , Dermatophagoides farinae , and B. tropicalis . Methods: Clinical records of 208 patients (5–65 years) with mite‐induced allergic rhinoconjunctivitis, with or without asthma, sensitized to these mites were analyzed. All received ≥ 12 months of SCIT. Follow‐up extended up to 5 years. Effectiveness was assessed annually using mixed models for repeated measures based on combined symptom and medication scores for rhinoconjunctivitis (RCSMS) and asthma (ACSMS), and individual symptom and medication scores. Safety was evaluated by recording adverse reactions. Results: Significant and sustained improvements were observed. Adjusted LS‐mean RCSMS decreased from 3.97 at baseline to 2.26 at 1 year and 1.24 at 5 years (−43.1% and −68.8%; p < 0.001). ACSMS decreased from 2.74 to 1.36 and 0.46 (−50.5% and −83.3%). Symptom improvement was early and accompanied by progressive reductions in medication use. Safety was favourable, with one mild grade 1 systemic reaction (0.48% of patients; 0.015% per injection), resolving without treatment modification. Conclusions: Triple‐mite SCIT was associated with sustained, clinically meaningful reductions in symptoms and medication use, and showed a favourable safety profile, supporting a favourable benefit–risk balance in regions where these mites coexist.

Verified
Journal Article
Open access
PDF file
FGFrancisco Javier Carballada Gonzalez
Francisco Javier Carballada Gonzalez
FGFernando García González
Fernando García González
BJBelén Hinojosa Jara
Belén Hinojosa Jara
FFFernando Rodríguez Fernández
Fernando Rodríguez Fernández
MGMiguel Añó García
Miguel Añó García
YGYara Ruiz García
Yara Ruiz García
Mite-induced allergic respiratory diseases are a major global health concern, and evidence on allergen immunotherapy (AIT) combining allergens from different mite families remains limited, particularly for Lepidoglyphus destructor. This study evaluated the effectiveness and safety of subcutaneous allergen immunotherapy containing glutaraldehydempolymerized extracts of Dermatophagoides pteronyssinus, Dermatophagoides farinae, and L. destructor in mite-allergic patients in Spain. This retrospective multicenter study included 199 patients with allergic rhinoconjunctivitis, with or without asthma. Effectiveness outcomes included combined symptom and medication scores (CSMS), symptom scores, and medication use. Safety outcomes included adverse reactions. Mixed models for repeated measures showed significant improvements in rhinoconjunctivitis and asthma outcomes (all p < 0.001). Adjusted LS-mean rhinoconjunctivitis CSMS decreased by 50.7% at T1 and 76.1% at T4; symptom and medication scores decreased by 85.3% and 69.3%, respectively, at T4. Asthma CSMS decreased by 43.1% at T1 and 89.0% at T5, while symptom and medication scores decreased by 93.4% and 88.5%, respectively. Similar patterns were observed in children. No systemic reactions occurred. Twenty mild local reactions were recorded in 17 patients (8.5%), corresponding to an estimated rate of 0.32% across 6169 injections. This AIT was associated with sustained clinical improvement and a favorable safety profile in adults and children.